Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

Exclusion Criteria

• •Patients who have had ≥ 2 relapses (defined as recurrence of any signs or symptoms attributable to active vasculitis) previously as patients with multiple prior relapses may be at higher risk of future relapse and require maintenance therapy
• •Patients with persistent low-grade disease activity ("grumbling" disease defined as BVAS \> 0 and ≤ 3)
• •Patients with active systemic infections or deep space infections within the 3 months prior to screening.
• •Patients participating in another clinical trial mandating maintenance therapy
• •Patients with drug-induced ANCA vasculitis (e.g. levamisole-adulterated cocaine)
• •Active tuberculosis, human immunodeficiency virus (HIV), hepatitis C virus or hepatitis B virus infections
• •For women of child-bearing potential, pregnancy, breastfeeding, unwillingness or inability to comply with effective contraception
• •Inability to come to scheduled visits